Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 12/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473981 | 0.82 | OPRK1 (0.48) | OPRK1ABL1KDM4EGAAATR | |
| SCHEMBL30816026 | 0.82 | OPRK1 (0.48) | OPRK1ABL1KDM4EGAAATR | |
| SCHEMBL28528395 | 0.82 | GABRG2 (0.41) | OPRK1ATRALDH1A1 | |
| SCHEMBL9383978 | 0.82 | CASP1 (0.47) | KDM4EGAATSHRALDH1A1GLA | |
| SCHEMBL21596479 | 0.82 | CA12 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL3520084 | 0.81 | MAPK1 (0.47) | ABL1KDM4EGAAATRTSHR | |
| SCHEMBL215798 | 0.81 | OPRK1 (0.47) | OPRK1KDM4EGAATSHRALDH1A1 | |
| SCHEMBL8091281 | 0.81 | OPRK1 (0.47) | OPRK1KDM4EGAATSHRALDH1A1 | |
| SCHEMBL31368194 | 0.81 | CA12 (0.49) | ABL1KDM4EGAAATRTSHR | |
| SCHEMBL26660324 | 0.81 | CA12 (0.49) | ABL1KDM4EGAAATRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380928-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-10-01 | — | — | EP | disclosed |
| CN-119998271-A | Pyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250122169-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024212941-A1 | CBL-B INHIBITOR | 北京诺诚健华医药科技有限公司 | 2024-10-17 | — | — | WO | disclosed |
| EP-4380928-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023014861-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-3810585-A1 | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2021-04-28 | — | — | EP | disclosed |
| US-20050203081-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081960-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-0265126-B1 | Process for the preparation of fused pyridine compounds | UNIV PRINCETON (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5250548-A | Treating hypertension, heart failure | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
| US-4988813-A | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1991-01-29 | — | — | US | disclosed |
| US-4902796-A | 6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1990-02-20 | — | — | US | disclosed |
| US-4818819-A | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0265126-A2 | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1988-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203081-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRS, PTPRO, PTPRM | OPRK1 4754/4885ABL1 77/4885KDM4E 899/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | OPRK1 2744/4885ABL1 3953/4885KDM4E 200/4885 |
| US-20250122169-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | OPRK1 362/4885ABL1 3447/4885KDM4E 4319/4885 |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | OPRK1 23/4885ABL1 1117/4885KDM4E 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.